Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Status:
Not yet recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion
study conducted in patients with advanced late stage cancer (pancreatic or gastric including
esophageal junction cancers) for which the investigator determines there to be no other
standard of care or higher priority therapies available.